Hector Medina and his co-founder moved their families to Tulsa in 2025 to build Monte Caldera Technologies. In a written interview with Build in Tulsa, he covers the company's pilots with Wheeler Bio, Bayer, and PPG, the Tulsa and Oklahoma organizations behind it, and the $5 million seed round ahead.
Monte Caldera Technologies (MCT) builds the Caldera Engine, an AI platform that predicts how complex formulations will behave before anything is mixed in a lab. Its first markets are biopharma formulations, such as monoclonal antibodies, and specialty chemicals. Hector Medina is the company's founder and CEO. Monte Caldera is one of five companies receiving $100,000 in funding through Build in Tulsa's 2026 Alumni BOOST Awards. Hunter McFarland, Build in Tulsa's Investor Relations Manager, asked the questions below.
Hunter McFarland: What are you raising next, and what technical milestones will this funding help you reach before you go to institutional investors and enterprise clients?
Hector Medina: We're raising a $5M seed round to scale the Caldera Engine platform and build our commercial team. Before then, we're using the BOOST Award and other non-dilutive funding to hit the milestones that matter most to institutional investors and enterprise buyers: proven results with real customers. Over the next several months, that means three things:
Together, these turn "promising technology" into documented performance with recognized industry partners. That is the evidence we'll take to seed investors and to our first enterprise contracts.
Hunter McFarland: You and your co-founder moved your families to Tulsa to build the company here. Which local and state resources have you used so far to build your presence?
Hector Medina: From the moment we arrived in 2025, Tulsa has welcomed us with remarkable generosity, and that support has shaped how we've built Monte Caldera here. A few organizations stand out: Tulsa Local Ventures and Atento Capital, Build in Tulsa, the University of Oklahoma, OKBioStart, and the George Kaiser Family Foundation. We've also worked with OCAST, OK Catalyst, the NSF Southeast Hub, the Tulsa Tech Council, Gradient, NYU Tulsa, Experience Tulsa, and the Tulsa Visa Network. And because we moved our families here too, community anchors like Council Oak Elementary have been part of making Tulsa home, not just headquarters.
Hunter McFarland: Which accelerators have backed Monte Caldera, and which steps along the way felt most validating?
Hector Medina: Our Tulsa story began with GRIDX to Tulsa, run by Atento Capital, which convinced us to relocate the company here. During that move, we were accepted into the Build in Tulsa Techstars accelerator, which came with our pre-seed investment. Since then we've gone through OKBioStart's Concept Program, where we were later selected for the Launch phase. Gradient has given us a home base and a steady connection to other founders.
The most validating moments came when industry and academic partners committed alongside us. One was formalizing our collaboration with the University of Oklahoma, especially the OU Bioprocessing Core at OKC. Another was Wheeler Bio, one of Oklahoma's leading biopharma companies, agreeing to pilot the Caldera Engine. Being named a 2026 BOOST Awardee confirmed that Tulsa is betting on us as much as we're betting on Tulsa.
Hunter McFarland: What can the Caldera Engine do that formulation scientists couldn't do before, and how long did that work take them previously?
Hector Medina: Developing a stable formulation for a biologic like a monoclonal antibody normally means trial and error at the lab bench: preparing and testing dozens to hundreds of conditions to find the ones where the drug won't clump, separate, or become too thick to inject. That cycle can take weeks to months per molecule and consumes scarce, expensive material. The Caldera Engine is built on physics rather than big datasets. It predicts how a formulation will behave across a whole design space from a small number of measurements, so scientists can rule out failing conditions before they ever touch a pipette. As a proof point, we reproduced a published 46,581-experiment phase-separation dataset from Novo Nordisk's research entirely in silico in under 3 days.
Learn more about Monte Caldera Technologies at montecaldera.com.